AnalystsAaron GalAaron Gal's Stock Forecasts
AnalystsAaron Gal
Analyst Ranking
Bottom 21%
#3975 out of 4989 analysts
Average Return
-2.72%
Win Rate
44%4 out of 9
Risk vs Reward
Poor
Good
Aaron Gal's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Gilead Sciences IncGILD | +35.91% | $87.36 | $118.73 | 2024‑10‑16 - 2025‑08‑20 | Buy |
Celgene CorpCELG | +20.65% | $77.66 | $93.70 | 2018‑05‑22 - 2019‑04‑01 | Buy |
Abbvie IncABBV | +19.91% | $135.42 | $162.38 | 2022‑01‑02 - 2023‑01‑03 | Buy |
Regeneron Pharmaceuticals IncREGN | +15.05% | $627.10 | $721.49 | 2022‑01‑02 - 2022‑12‑30 | Buy |
Aaron Gal Analyst Color
Get additional color on Aaron Gal's coverage of popular stocks
Aaron Gal's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Gilead Sciences IncGILD | 3 | Buy | $105.00 | -11.56% | Initiates Coverage On | 10 months ago |
Abbvie IncABBV | 2 | Hold | $203.00 | -2.94% | Initiates Coverage On | 10 months ago |
Amgen IncAMGN | 2 | Buy | $380.00 | +28.18% | Initiates Coverage On | 10 months ago |
Regeneron Pharmaceuticals IncREGN | 3 | Buy | $1,125.00 | N/A | Initiates Coverage On | a year ago |
Biogen IncBIIB | 2 | Buy | $500.00 | N/A | Upgrades | 4 years ago |
Viatris IncVTRS | 1 | Hold | $21.00 | N/A | Initiates Coverage On | 5 years ago |
Celgene CorpCELG | 4 | Hold | N/A | N/A | Downgrades | 6 years ago |
Teva Pharmaceutical Industries LtdTEVA | 1 | Hold | N/A | N/A | Downgrades | 8 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.